IP Library Granted Patent US 9,526,911
Granted Patent B1
US 9,526,911 · App. 13/095,804 · Granted Dec 27, 2016

Immune mediated cancer cell destruction, systems and methods

Inventors: Larry Azure (La Conner, WA); Charles E. Hill (Issaquah, WA); Andrew L. Azure (Mount Vernon, WA); Rafael Ponce (Seattle, WA); Lawrence L. Kunz (Greenbank, WA)
Assignee: LAZURE SCIENTIFIC, INC.
A61N1/403A61N5/025A61N5/0625A61B18/14A61B18/1477A61B18/18A61B2017/00867A61B2018/0016A61B2018/143A61B2018/1425A61B2018/1432A61B2018/1475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,526,911
App. No.
13/095,804
Granted
Dec 27, 2016
Kind
B1
Abstract

Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.

Claims (29)

1. A method for delivering electric fields to a target tissue of a patient for destruction of cancerous cells, comprising:

identifying a first target tissue site having cancer cells to destroy with remote electrical current flow treatment at an identified second target tissue site, the first identified target tissue site remote from the second identified target tissue site; and

based on the step of identifying the first target tissue site, establishing an electrical current flow through an electrical treatment volume of the target tissue at the second identified target tissue site so as to preferentially destroy cancerous cells located in the electrical treatment volume and wherein the electrical current flow at the second identified target tissue site induces a specific anti-cancerous cell immune response in the patient to treat the first identified target tissue site.

2. The method of claim 1 , wherein the electrical current flow is selected such that thermal based protein coagulation and denaturation in the cancerous cells or tissue is substantially avoided.

3. The method of claim 1 , wherein the second target tissue is heated to less than about 50 degrees C. during a phase of treatment.

4. The method of claim 1 , wherein the electrical current flow provides a voltage field less than about 50 V/cm.

5. The method of claim 1 , wherein the electrical current flow comprises a frequency between about 50 kHz and about 300 kHz.

6. A method for delivering electric fields to a target tissue of a patient for destruction of cancerous cells, comprising:

identifying a first target tissue site having cancer cells to destroy with remote electrical current flow treatment at a second identified target tissue site, the first identified target tissue site remote from the second identified target tissue site; and

based on the step of identifying the first target tissue site, eliciting destruction of cancerous cells of the first identified target tissue site by establishing an electrical current flow through a volume of the second identified target tissue site so as to preferentially destroy cancerous cells in the electrical treatment volume;

wherein a specific host anti-cancerous cell immune response is induced at the second identified target tissue site so as to control growth of cancerous cells at the first identified target tissue site that has not directly received electrical current flow.

7. The method of claim 6 , wherein cancerous cells have been seeded at the second target tissue site.

8. The method of claim 6 , wherein the electrical current flow is selected such that thermal based protein coagulation and denaturation in the cancerous cells or tissue is substantially avoided.

9. The method of claim 6 , wherein the second target tissue is heated to less than about 50 degrees C.

10. The method of claim 6 , wherein the electrical current flow provides a voltage field less than about 50 V/cm.

11. The method of claim 6 , wherein the electrical current flow comprises a frequency between about 50 kHz and about 300 kHz.

12. A method for delivering electric fields to a target tissue of a patient for destruction of cancerous cells, comprising:

identifying a first target tissue site having cancer cells to destroy with remote electrical current flow treatment at an identified second target tissue site, the first identified target tissue site remote from the second identified target tissue site;

based on the step of identifying the first target tissue site, establishing an electrical current flow through an electrical treatment volume of the target tissue at the second identified target tissue site so as to preferentially destroy cancerous cells located in the electrical treatment volume and wherein the electrical current flow at the second identified target tissue site induces a specific anti-cancerous cell immune response in the patient to treat the first identified target tissue site; and

administering an immunostimulatory agent or adjuvant to the patient.

13. The method of claim 12 , wherein the administering an immunostimulatory agent or adjuvant to the patient comprises a systemic administration.

14. The method of claim 12 , wherein the administering an immunostimulatory agent or adjuvant to the patient comprises a local administration.

15. A method for delivering electric fields to a target tissue of a patient for destruction of cancerous cells, comprising:

identifying a first target tissue site having cancer cells to destroy with remote electrical current flow treatment at a second identified target tissue site, the first identified target tissue site remote from the second identified target tissue site;

based on the step of identifying the first target tissue site, eliciting destruction of cancerous cells of the first identified target tissue site by establishing an electrical current flow through a volume of the second identified target tissue site so as to preferentially destroy cancerous cells in the electrical treatment volume;

wherein a specific host anti-cancerous cell immune response is induced at the second identified target tissue site so as to control growth of cancerous cells at the first identified target tissue site that has not directly received electrical current flow; and

administering an immunostimulatory agent or adjuvant to the patient.

16. The method of claim 15 , wherein the administering an immunostimulatory agent or adjuvant to the patient comprises a systemic administration.

17. The method of claim 15 , wherein the administering an immunostimulatory agent or adjuvant to the patient comprises a local administration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2015
From: LAZURE TECHNOLOGIES, LLC
To: LAZURE SCIENTIFIC, INC.
Reel/Frame 034706/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2012
From: AZURE, LARRY
To: LAZURE TECHNOLOGIES, LLC
Reel/Frame 029382/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2012
From: HILL, CHARLES E.; AZURE, ANDREW L.; PONCE, RAFAEL; KUNZ, LAWRENCE L.
To: LAZURE SCIENTIFIC, INC.
Reel/Frame 029384/0102 →
Continuity (1)
Provisional Application 61328580 · Apr 27, 2010